search
Back to results

Transfusion Requirements in Gastrointestinal (GI) Bleeding

Primary Purpose

Upper Gastrointestinal Bleeding, Cirrhosis, Portal Hypertension

Status
Unknown status
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
red blood cell transfusion
Sponsored by
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Upper Gastrointestinal Bleeding focused on measuring Upper GI bleeding, Cirrhosis, Portal hypertension, Non-variceal bleeding, Transfusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients with acute upper GI hemorrhage who do not have any criterion of exclusion.

Exclusion Criteria:

  • < 18 years old.
  • Pregnancy.
  • Negative of the patient to receive transfusions.
  • Negative of the patient to participate in the study.
  • Patients with therapeutic restrictions (as terminally ill patients).
  • Previous recent surgery requiring transfusion.
  • Recent (less than 90 days) or unstable acute myocardic ischemia. Peripheral vasculopathy with secondary.
  • To have been included in this same study in the 30 previous days.

Sites / Locations

  • Unidad de Sangrantes, HSCSPRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1

2

Arm Description

Regular transfusion

Restricted transfusion

Outcomes

Primary Outcome Measures

Mortality at the 45th day

Secondary Outcome Measures

Mortality at the 7th and 45th day
Rebleeding
Transfusion requirements
Liquids requirements
Portal pressure changes
Complications

Full Information

First Posted
December 21, 2006
Last Updated
December 28, 2010
Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
search

1. Study Identification

Unique Protocol Identification Number
NCT00414713
Brief Title
Transfusion Requirements in Gastrointestinal (GI) Bleeding
Official Title
Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2010
Overall Recruitment Status
Unknown status
Study Start Date
October 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2007 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Recently it has been suggested that a restrictive transfusion of units of Red Cells (URC) may improve the outcome of ICU patients with anemia. Furthermore, it has been suggested that the transfusion of URC may be deleterious for the hemostatic process of bleeding lesions, which suggest that a restrictive transfusion may be valuable in patients which gastrointestinal bleeding. Transfusion of URC may also increase portal pressure which may be detrimental to control acute portal hypertensive bleeding. The aim of the present study is to assess whether a restrictive transfusions may improve the outcome of patients with acute nonvariceal gastrointestinal bleeding, and also whether such a restrictive strategy may improve the outcome of bleeding episodes related with portal hypertension. The study will be carried out with a prospective, randomized and controlled design comparing the restrictive transfusion strategy with the usual nonrestrictive transfusional strategy. Overall 860 patients will be included; 430 in each group. The main outcome measure will be survival. All deaths occurred within the 30 days after admission, will be considered. Secondary outcomes will include rebleeding and complications related to treatment, and related to the bleeding episode itself. Portal pressure will be measured to assess the influence of the transfusions strategy on fluctuations of this parameter, and the relationship with the clinical course of bleeding episode. The study will be performed at the Bleeding Unit of our hospital during a period of 3 years.
Detailed Description
HYPOTHESIS At the present time there does not exist established criteria to decide when it is necessary a blood transfusion in a patient with digestive hemorrhage, neither which should be the red cells concentrates (RBC) amount that the most of the patients will need. In clinical studies made in critical patients undergoing a by-pass coronary surgery, the strategy of restrictive transfusion showed results similar to the one obtained with more liberal strategies, even with an improvement of the survival and a smaller rate of complications related to transfusion. In animal models of GI bleeding (and also in human studies in the traumatic hemorrhage), precocious or vigorous transfusion made hemostasia more difficult. Also an increase in the rate of rebleeding has been observed, suggesting that arterial hypotension combined with hypovolemia aid hemostasia, stabilize the clot. It leads to diminish by itself the rebleeding rate. In the same way, in patients with portal hypertension associated hemorrhage, aggressive replacement of volemia causes increases on the portal pressure, and that could lead in a condition of bigger difficulty for the control of the hemorrhage and greater rate of recidiva. On the other hand, potential complications associated with the transfusion would be seen potentially reduced. Our randomized prospective study tries to demonstrate that the use of a restrictive strategy in the sanguineous transfusion in patients with acute GI upper bleeding can be at least as beneficial than the habitually used. Moreover, restricted transfusion in these patients could improve short term survival, as well as a smaller rate transfusion-related or rebleeding. In portal hypertension related hemorrhage, restricted transfusion could avoid fluctuations of portal pressure caused by transfusion during the acute phase of hemorrhage, which could favor hemostasia in these patients. OBJECTIVES The main objective is to evaluate if restrictive transfusion criterion in patients with acute upper GI hemorrhage can maintain the rates of survival obtained using habitual transfusion criteria, or to even improve them. The more important secondary targets consist in evaluating if these restrictive transfusional parameters are also accompanied by a better control of the hemorrhage, and also to evaluate if this is accompanied by a smaller rate of complications. Other additional objectives would be: Effect on changes in portal pressure and its correlation with the clinical evolution. Hospital stay and estimation of economic cost. STUDY DESIGN Ours is a prospective, randomized and controlled study, in which patients with acute upper GI bleeding will be randomized into two groups of transfusional RBC treatment with: Group 1 (of restricted transfusion), that constitutes the training group: they will receive UCH transfusion when the hemoglobin descends below 70 G/L, to maintain values of hemoglobin of 70 to 90 G/L. Group 2 (of habitual transfusion), that constitutes the group control: they will receive transfusion according to habitual practice, when the hemoglobin descends below 90 G/L, to maintain values of hemoglobin of 90 to 110 G/L. Randomization will be made by means of a closed opaque envelope that will contain the treatment option that will have been obtained by means of a listing of random numbers generated by computer. The patients will be randomized as soon as the inclusion criteria/exclusion has been verified. Randomization will be stratified according to the origin of the hemorrhage (related to portal hypertension or not). NUMBER OF PREDICTED SUBJECTS AND JUSTIFICATION: 430 patients in every group will be required (860 altogether), to objective a mortality reduction of 5%, with a global expected mortality secondary to GI bleeding at the control group of 10%, with a type I error of 5% and a type II error of 20%. 280 patients in each group will be required (560 altogether) to objective a difference of 6%, with the detailed parameters. An expected period of 3 years to include this

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Upper Gastrointestinal Bleeding, Cirrhosis, Portal Hypertension
Keywords
Upper GI bleeding, Cirrhosis, Portal hypertension, Non-variceal bleeding, Transfusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
860 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Regular transfusion
Arm Title
2
Arm Type
Active Comparator
Arm Description
Restricted transfusion
Intervention Type
Procedure
Intervention Name(s)
red blood cell transfusion
Intervention Description
red blood cell transfusion
Primary Outcome Measure Information:
Title
Mortality at the 45th day
Time Frame
45 days
Secondary Outcome Measure Information:
Title
Mortality at the 7th and 45th day
Time Frame
45 days
Title
Rebleeding
Time Frame
45 days
Title
Transfusion requirements
Time Frame
45 days
Title
Liquids requirements
Time Frame
45 days
Title
Portal pressure changes
Time Frame
7 days
Title
Complications
Time Frame
45 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients with acute upper GI hemorrhage who do not have any criterion of exclusion. Exclusion Criteria: < 18 years old. Pregnancy. Negative of the patient to receive transfusions. Negative of the patient to participate in the study. Patients with therapeutic restrictions (as terminally ill patients). Previous recent surgery requiring transfusion. Recent (less than 90 days) or unstable acute myocardic ischemia. Peripheral vasculopathy with secondary. To have been included in this same study in the 30 previous days.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Càndid - Villanueva, DR.
Phone
+34620955006
Email
cvillanueva@santpau.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Càndid Villanueva, DR
Organizational Affiliation
HSCSP
Official's Role
Principal Investigator
Facility Information:
Facility Name
Unidad de Sangrantes, HSCSP
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Càndid Villanueva, DR
Phone
+34620955006
Email
cvillanueva@santpau.es
First Name & Middle Initial & Last Name & Degree
Càndid Villanueva, DR

12. IPD Sharing Statement

Citations:
PubMed Identifier
34932836
Citation
Carson JL, Stanworth SJ, Dennis JA, Trivella M, Roubinian N, Fergusson DA, Triulzi D, Doree C, Hebert PC. Transfusion thresholds for guiding red blood cell transfusion. Cochrane Database Syst Rev. 2021 Dec 21;12(12):CD002042. doi: 10.1002/14651858.CD002042.pub5.
Results Reference
derived
PubMed Identifier
23281973
Citation
Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, Graupera I, Poca M, Alvarez-Urturi C, Gordillo J, Guarner-Argente C, Santalo M, Muniz E, Guarner C. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21. doi: 10.1056/NEJMoa1211801. Erratum In: N Engl J Med. 2013 Jun 13;368(24):2341.
Results Reference
derived

Learn more about this trial

Transfusion Requirements in Gastrointestinal (GI) Bleeding

We'll reach out to this number within 24 hrs